Ovarian Cancer CRO
Specialized support for ovarian cancer trials from first-in-human through global Phase III
Worldwide helps sponsors design and run ovarian cancer and other gynecologic oncology trials with expertise built around biomarker-driven populations, cooperative group dynamics, complex response assessment, and the operational realities that can shape speed, consistency, and data quality across phases.
Tell us about your study
We’ll connect you with the right oncology clinical
development team.
Your Ovarian Cancer Trial Challenges
Why Ovarian Cancer Trials Need Specialized Support
Ovarian cancer trials can be more complex than sponsors expect because the challenges are not only operational. Study execution is often shaped by cooperative group dynamics, difficult response assessments, biomarker strategy, and regional variation in standards of care. Those factors can affect how quickly a study starts or enrolls, how consistently endpoints are interpreted, and how confidently a program moves forward. Worldwide helps sponsors manage that complexity with ovarian cancer-specific expertise, experienced global teams, and support organized around how these studies actually run.
Cooperative Group Complexity Affects Execution
Cooperative groups can strengthen ovarian cancer research, but they can also affect startup, governance, budgets, site prioritization, and enrollment timelines. Worldwide brings experience working within and alongside global cooperative groups such as GOG and ENGOT.
Endpoint Consistency Requires Ovarian Expertise
Ovarian cancer response assessment is not always straightforward, yet requires consistent interpretation across sites. Worldwide supports study teams and sites with ovarian-specific training and central radiology approaches that help strengthen consistency.
Biomarker Planning Shapes Program Potential
In ovarian cancer, biomarker strategy can influence eligibility, enrollment, subgroup analysis, and how confidently a program moves forward. Worldwide supports biomarker-driven development with operational planning aligned to study goals and program needs.
Global Variation Can Complicate Study Conduct
Global ovarian cancer studies can be affected by regional variations in standard of care, including protocols that use investigator’s choice (IC) chemotherapy. Worldwide helps sponsors plan for that variation without losing consistency in study execution or endpoint review.
Partnership & Approach
An Indication-Aware Partner for Ovarian Cancer Trial Success
Ovarian cancer requires more than general oncology support. Worldwide partners with sponsors around the full trial ecosystem, including cooperative group dynamics, patient referral pathways, endpoint consistency, biomarker-driven design, and global operational demands. An indication-aware approach helps teams protect both speed and data quality as programs move across phases and regions.
Studies in the Past
Five Years
Patients Enrolled
Unique Sites
Why Worldwide
What Makes Worldwide the Right Ovarian Cancer Trial Fit?
Worldwide brings ovarian cancer trial expertise across Phases I-III along with global operational experience built around the demands sponsors face in this indication.
Deep Ovarian Cancer Expertise
Ovarian cancer is one of Worldwide’s most established indication areas, with experience across first-in-human with novel drug classes to large, global studies that support FDA approval. That depth helps sponsors work with teams who understand how this disease impacts study execution.
Countries
Created for Cooperative Group Realities
Worldwide brings practical experience working alongside cooperative group models such as GOG and ENGOT. That matters in an indication where the participation of these groups can significantly influence your site selection and enrollment success.
Endpoint Discipline That Supports Consistency
Ovarian-specific training tied to response measures such as RECIST and CA-125 helps study teams manage one of the indication’s most important operational risks: inconsistent endpoint interpretation across sites and regions.
Continuity Across Development Stages
Worldwide supports ovarian cancer development from first-in-human through global Phase III and approval. That phase-spanning support helps sponsors maintain momentum across the development continuum.
Experience Across Biomarkers & Modalities
Worldwide supports biomarker-driven ovarian cancer programs and has experience across evolving modalities and disease settings, including antibody-drug conjugates, tyrosine kinase inhibitors and cell therapy, each of which require specialized operational planning.
Services & Capabilities
Comprehensive Oncology CRO Services
- Protocol Design and Clinical Development Planning
- Regulatory Consulting and Global Submissions
- Global Project Management
- Feasibility Analysis and Site Selection Strategy
- Site Initiation and Study Start-up
- Patient Enrollment
- Dose Escalation, Optimization and Cohort Management
- Site Monitoring and Management
- Data Management
- Clinical Data Analytics and Review
- Clinical Science
- Biostatistics
- Medical Monitoring
- Safety / Pharmacovigilance
- Medical Writing
Cooperative Group Trial Management
Worldwide helps sponsors plan cooperative group governance, startup, budgets, and site prioritization in an indication where these factors can materially affect timelines and execution.
Biomarker-Driven Study Support
Our teams support ovarian cancer programs shaped by biomarkers such as HRD, BRCA, FRα, and CA-125, helping align operational planning with eligibility, enrollment, and analysis needs.
Endpoint Consistency & Central Review
Worldwide supports consistent interpretation across sites through ovarian-specific training and central radiology approaches that fit the complexity of response assessment in this disease.
Global Ovarian Trial Execution
With experience across 19 countries and 320+ unique sites, Worldwide helps sponsors manage global execution while staying attentive to regional standard-of-care variation and operational consistency.
What Our Clients Say
“Something of importance is not to have a vendor, which is always in agreement with the sponsor. It’s always better to have a CRO partner who is able to challenge our thinking and make new proposals. (…) And it was, honestly, part of the decision why we selected Worldwide Clinical Trials.”
Head of Clinical Operations – Late Phase | Biotech Customer
FAQ & Insights
What Sponsors Need to Know
Ovarian cancer trials can be more complex because disease presentation, biomarker-driven populations, and response assessment often require more specialized planning than sponsors expect. Cooperative group involvement, patient referral patterns, and variations in standard of care can also shape how studies are designed and executed across regions.
Worldwide brings experience working within and alongside cooperative group models such as GOG and ENGOT. That experience helps teams plan more realistically around governance, startup, site prioritization, and enrollment considerations that can affect ovarian cancer trial timelines and execution.
Worldwide supports consistency through ovarian-specific CRA and study-team training, along with central radiology approaches where appropriate. That matters in ovarian cancer, where disease patterns and endpoint interpretation can create variability if sites are not aligned.
Worldwide supports biomarker-driven ovarian cancer development across programs that involve markers such as HRD, BRCA, FRα, and CA-125. Our teams help align operational planning with study eligibility, patient identification, and the broader needs of biomarker-informed trial design.
Yes. Worldwide supports ovarian cancer development from first-in-human through global Phase III, including seamless or master protocols that blend phases of development. That phase-spanning support helps sponsors work with a team that can stay aligned as the program evolves.
Ovarian cancer patients are often diagnosed in community gynecology settings before moving to specialty gynecologic oncology centers, which can complicate referral and enrollment planning. Worldwide understands those pathways and helps sponsors build study execution strategies that reflect how patients are identified and referred in practice.
Regional variation can be especially relevant in ovarian cancer, where study designs often allow IC chemotherapy. Worldwide helps sponsors account for those differences in global study planning and execution so regional practice patterns do not undermine consistency.
Central radiology is an important tool for helping preserve endpoint consistency and data integrity in ovarian cancer trials, especially because response per RECIST can be difficult to interpret due to small and scattered target lesions. The decision depends on the needs of the study, but Worldwide has experience leveraging central radiology and always recommends it for late phase development.
Oncology Expertise
Looking for Other Oncology Specializations?
See what Worldwide Clinical Trials can do for you.
Your study has unique goals, risks, and decisions ahead. Tell us a little about your needs, and our team will connect you with the right Worldwide experts to discuss how our scientific, medical, and operational support can help move your program forward with confidence.
